These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2222547)

  • 1. [Biochemical aspects of the evaluation of fixed drug combinations].
    Roebruck P; Unkelbach HD; Vollmar J; Köpcke W; Fassl H; Ferner U; Fink H; Junge K; Nowak H; Widdra W
    Arzneimittelforschung; 1990 Jul; 40(7):725-9. PubMed ID: 2222547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fixed drug combinations--the pros and the cons].
    Rustenbeck I
    Med Monatsschr Pharm; 2009 Apr; 32(4):141-6. PubMed ID: 19445271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment of risks, benefits and availability of non-narcotic analgesics. A commonsense approach.
    Darmansjah I
    Med Toxicol; 1986; 1 Suppl 1():115-20. PubMed ID: 3821425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach to the assessment of therapeutic drug interactions with fixed combination drug products.
    Rockhold FW; Goldberg MR
    J Biopharm Stat; 1996 Jul; 6(3):231-40. PubMed ID: 8854228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How to evaluate the contribution of fixed dose combinations: the standpoint of the methodologist].
    Chatellier G
    J Hum Hypertens; 1995 Aug; 9 Suppl 4():S27-33. PubMed ID: 7674270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The danger of fixed drug combinations.
    Herxheimer H
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):70-3. PubMed ID: 1165144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combinations improve medication compliance: a meta-analysis.
    Bangalore S; Kamalakkannan G; Parkar S; Messerli FH
    Am J Med; 2007 Aug; 120(8):713-9. PubMed ID: 17679131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach.
    Orloff DG
    Am J Cardiol; 2005 Nov; 96(9A):28K-33K; discussion 34K-35K. PubMed ID: 16291011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology and rationale of analgesic combinations.
    Desmeules J; Rollason V; Piguet V; Dayer P
    Eur J Anaesthesiol Suppl; 2003; 28():7-11. PubMed ID: 12785456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed drug combinations in the treatment of hypertension: how to identify the optimal dose.
    Messerli FH; Michalewicz L
    J Hypertens Suppl; 1998 Jan; 16(1):S81-4. PubMed ID: 9534103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
    Rabbani A; Alexander GC
    Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.
    Laing RO; McGoldrick KM
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.